QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Price, News & Analysis

$5.50
-0.30 (-5.17%)
(As of 05:22 PM ET)
Today's Range
$5.43
$5.96
50-Day Range
$1.90
$10.13
52-Week Range
$1.87
$40.58
Volume
2.20 million shs
Average Volume
4.43 million shs
Market Capitalization
$325.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.75

Ventyx Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
295.5% Upside
$21.75 Price Target
Short Interest
Bearish
20.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Ventyx Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.55) to ($2.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

Medical Sector

500th out of 938 stocks

Pharmaceutical Preparations Industry

230th out of 425 stocks

VTYX stock logo

About Ventyx Biosciences Stock (NASDAQ:VTYX)

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

VTYX Stock Price History

VTYX Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
VTYX Apr 2024 17.500 call
VTYX Apr 2024 10.000 put
See More Headlines
Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTYX
Fax
N/A
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.75
High Stock Price Target
$62.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+274.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-192,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.13 per share

Miscellaneous

Free Float
44,800,000
Market Cap
$343.95 million
Optionable
Optionable
Beta
0.36
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Sheila K. Gujrathi M.D. (Age 54)
    Executive Chairperson
    Comp: $125k
  • Dr. Raju S. Mohan Ph.D. (Age 67)
    Founder, CEO, President & Director
    Comp: $989.99k
  • Dr. John M. Nuss Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $656.99k
  • Dr. Martin Douglas Auster M.D. (Age 49)
    Chief Financial Officer
  • Mr. Christopher W. Krueger J.D. (Age 56)
    MBA, Chief Business Officer
    Comp: $568.14k

VTYX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VTYX shares.
View VTYX analyst ratings
or view top-rated stocks.

What is Ventyx Biosciences' stock price target for 2024?

9 brokers have issued 12 month target prices for Ventyx Biosciences' shares. Their VTYX share price targets range from $5.00 to $62.00. On average, they predict the company's share price to reach $21.75 in the next twelve months. This suggests a possible upside of 295.5% from the stock's current price.
View analysts price targets for VTYX
or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2024?

Ventyx Biosciences' stock was trading at $2.47 at the beginning of the year. Since then, VTYX stock has increased by 122.7% and is now trading at $5.50.
View the best growth stocks for 2024 here
.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VTYX earnings forecast
.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.08. During the same period in the prior year, the firm earned ($0.62) EPS.

When did Ventyx Biosciences IPO?

Ventyx Biosciences (VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.

Who are Ventyx Biosciences' major shareholders?

Ventyx Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.34%), Vanguard Group Inc. (6.32%), Capital International Investors (3.99%), Goldman Sachs Group Inc. (2.31%), Goldman Sachs Group Inc. (2.30%) and Opaleye Management Inc. (1.93%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White.
View institutional ownership trends
.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTYX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners